KIDNEY TRANSPLANT REJECTION

This study tests whether the drug frexalimab can prevent kidney transplant rejection better than the standard drug tacrolimus. About 526 adults receiving their first kidney transplant will be randomly assigned to one of the two treatments and followed for up to 5 years. The main …

This early-stage trial tests two drugs, carfilzomib and belatacept, in 25 kidney transplant recipients who have a type of rejection called antibody-mediated rejection. The goal is to see if the combination is safe and can reduce harmful antibodies or improve kidney function over …

This study tests whether adding the drug tocilizumab to standard treatment (plasmapheresis, IVIG, and rituximab) can better treat chronic active antibody-mediated rejection in kidney transplant recipients. About 50 participants will be enrolled to see if the combination improves …

This study tests whether a blood test that measures donor DNA (dd-cfDNA) can safely guide follow-up care for kidney transplant patients, potentially reducing the need for invasive biopsies. 500 adult kidney transplant recipients will be randomly assigned to standard care or a str…

This study tests whether a urine test for a protein called CXCL10 can catch kidney transplant rejection that a standard blood test misses. Researchers will compare the urine test to biopsy results in 50 kidney transplant patients. They will also check if the urine samples can be …

This study is testing whether a blood test (called DD-cfDNA) can accurately detect kidney transplant rejection, potentially replacing the need for invasive kidney biopsies. Researchers will compare the blood test results with standard biopsy analysis in 300 kidney transplant reci…

This study is looking at whether changes in platelet function can signal acute rejection in kidney transplant recipients. Researchers will measure platelet activity before and after transplant, and at times of suspected rejection. The goal is to develop a non-invasive blood test …

This study is testing whether a donor-derived cell-free DNA (dd-cfDNA) test can accurately detect rejection in kidney transplant recipients. Researchers will compare the test results to standard biopsy findings in 125 adults who are at least 12 days post-transplant. If the test w…

This study explores whether a special type of MRI, called manganese-enhanced MRI, can help identify people with kidney disease who are at risk for heart problems. Researchers will scan the heart and kidneys of 120 adults with various kidney conditions, including acute kidney inju…